Sign up for our daily Newsletter and stay up to date with all the latest news!

Subscribe I am already a subscriber

Sign up for our daily Newsletter and stay up to date with all the latest news!

Subscribe I am already a subscriber

CAN (ON): Organigram pauses production of certain products because of mislabeling

Organigram Holdings has received notification from Health Canada that Health Canada has determined that certain Jolts lozenge products in their 100 mg THC per package format (the “Products”) have been improperly classified as an “extract” rather than an “edible” under the Cannabis Regulations. The Company launched the Products in August 2021 following significant research, development, and regulatory work. The Company remains of the view that the patent-pending Products are properly classified as cannabis extracts and compliant with the Cannabis Regulations and is assessing its options with its legal advisors.

At present, the Company has paused production of the Products in the current packaging format, pending resolution of the matter. According to Health Canada’s notification, the Company can continue to sell and distribute inventory of the Products until May 31, 2023.

For more information:
Organigram
organigram.ca 

Publication date: